JOURNAL OF ADVANCED ELECTRICAL AND ELECTRONIC ENGINEERING

Vol 1 Issue 3 (2025)

http://jaeee.org/

Impact of RNA-Based Viral Infections on Liver Enzyme Profiles in Chronic Liver Disease Patients

Carlos M. Navarro
Department of Hepatology and Infectious Diseases, Universidad Nacional de Medicina, Mexico City, Mexico

Email: *c.navarro@univmed.mx*

Abstract

Chronic liver diseases (CLDs) associated with RNA-based viral infections, particularly Hepatitis C Virus (HCV) and Hepatitis E Virus (HEV), exhibit diverse biochemical profiles that can reflect both the severity of hepatic injury and the nature of the viral insult. This study investigates the differential impact of HCV and HEV on liver enzyme markers in CLD patients, focusing on transaminases, cholestatic markers, and synthetic function indicators. Through quantitative analysis of serum ALT, AST, ALP, GGT, bilirubin, albumin, and INR, alongside viral RNA load, we demonstrate that HCV patients typically present with elevated ALT levels compared to HEV patients, while cholestatic markers such as ALP and GGT show moderate elevations in both groups. These findings provide critical insights into hepatic dysfunction patterns and underscore the role of liver enzymes as non-invasive markers for disease monitoring and therapeutic guidance in viral hepatitis.

Keywords

Hepatitis C Virus (HCV), Hepatitis E Virus (HEV), Liver Enzymes, ALT, Chronic Liver Disease, Biomarkers

INTRODUCTION

Chronic infections with RNA viruses such as HCV and HEV remain major etiological factors for liver dysfunction globally, especially in resource-constrained settings. These pathogens exhibit tropism for hepatocytes, initiating processes of necroinflammation, fibrosis, and cirrhosis. Liver enzyme profiles—particularly transaminases, bilirubin, and cholestatic enzymes—offer essential clinical insight into hepatic injury and progression. Although both HCV and HEV may culminate

in chronic hepatic damage, their pathophysiology and biochemical signatures differ. This study evaluates the alterations in liver enzyme profiles among patients with RNA virus-induced CLD, aiming to establish correlations with viral load and disease severity.

Molecular Virology of HCV and HEV

Genome Structure

Hepatitis C Virus (HCV) and **Hepatitis E Virus (HEV)** are both positive-sense, single-stranded RNA viruses, but they belong to distinct viral families and exhibit unique genomic and structural characteristics:

- **HCV** is classified under the *Flaviviridae* family, genus *Hepacivirus*. It possesses a ~9.6 kb RNA genome organized into a single open reading frame (ORF) flanked by 5′ and 3′ untranslated regions (UTRs). The ORF encodes a single polyprotein that is co- and post-translation ally cleaved into **structural proteins** (Core, E1, and E2) and **non-structural proteins** (NS2, NS3, NS4A, NS4B, NS5A, NS5B).
- **HEV** belongs to the *Hepeviridae* family, genus *Orthohepevirus*, with a genome of approximately 7.2 kb comprising three ORFs:
    - **ORF1** encodes nonstructural proteins including helicase, protease, and RNA-dependent RNA polymerase (RdRp),
    - **ORF2** encodes the capsid protein,
    - **ORF3** encodes a small multifunctional phosphoprotein involved in viral egress and immune evasion.

Replication Cycles

Both HCV and HEV replicate within hepatocytes, yet their strategies vary:

- **HCV replication** occurs in the cytoplasm, closely associated with **host lipid membranes** forming the "membranous web." The viral RdRp (NS5B) synthesizes negative-strand RNA intermediates that serve as templates for producing new positive-sense genomes. Viral particles assemble on lipid droplets and are released via the VLDL secretion pathway.
- **HEV replication** is also cytoplasmic and involves RdRp-mediated transcription of negative-sense intermediates followed by generation of subgenomic RNA. The virus particles are released both in **non-enveloped (feces)** and **quasi-enveloped (serum)** forms, contributing to distinct transmission routes.

Mechanisms of Chronicity

The persistence of viral infection and progression to chronic liver disease is more established for HCV, whereas HEV chronicity is primarily observed in **immunocompromised individuals** (e.g., organ transplant recipients):

- **HCV chronicity** is driven by:
    - **Immune evasion** mechanisms, including rapid mutation in hypervariable regions, inhibition of interferon signaling (via NS3/4A and NS5A), and the establishment of T-cell exhaustion.
    - **Viral quasispecies diversity**, which allows escape from adaptive immune responses.
    - **Induction of fibrosis** via upregulation of pro-fibrogenic cytokines like TGF-β.
- **HEV chronic infection** is rare in immunocompetent hosts but may persist in immunosuppressed individuals. Mechanisms include:
    - Downregulation of innate immune responses, especially type I interferons,
    - Suppression of antigen presentation,
    - Occasional emergence of mutations in the polymerase gene that enhance replication fitness.

Overall, the **molecular virology of HCV and HEV** highlights both the convergence in their hepatotropism and the divergence in their chronicity profiles. Understanding these mechanisms is critical for antiviral development and vaccine research.

Global Burden and Epidemiological Trends

Hepatitis C Virus (HCV)

HCV continues to pose a major public health challenge worldwide, with an estimated **58 million people living with chronic HCV infection** and approximately **1.5 million new infections** occurring annually, according to the World Health Organization (WHO, 2022). The disease burden is **disproportionately higher in LMICs**, where access to diagnostic tools and antiviral therapies remains limited.

- **Prevalence Hotspots**:
    - The **Eastern Mediterranean Region (EMR)** and parts of **Sub-Saharan Africa** report the highest prevalence rates, with Egypt historically having rates exceeding 10%, although recent national efforts have led to a sharp decline.
    - In **South Asia**, Pakistan, India, and Bangladesh exhibit intermediate to high HCV seroprevalence due to unsafe medical practices, transfusions, and injectable drug use.
- **Demographic Risk Groups**:
    - **Middle-aged adults (35–60 years)** are more likely to harbor chronic infection due to cumulative exposure risks.
    - **Intravenous drug users (IDUs)** and recipients of **unscreened blood products** remain high-risk groups.
    - **Incarcerated individuals** and **healthcare workers** are also vulnerable due to occupational and environmental exposures.

Hepatitis E Virus (HEV)

HEV accounts for approximately **20 million infections annually**, leading to over **70,000 deaths**, largely through fulminant hepatitis in high-risk populations. Unlike HCV, HEV is primarily transmitted through **fecal-oral routes**, particularly in areas with poor sanitation.

- **Epidemiological Patterns**:
  - Endemic in **South Asia**, **East Africa**, and **Southeast Asia**, HEV outbreaks are typically linked to contaminated water sources.
  - **Genotype 1 and 2** dominate in developing regions and are associated with large waterborne outbreaks.
  - **Genotype 3 and 4**, which can infect animals, are more common in high-income countries and are often transmitted zoonotically.
- **High-Risk Populations**:
  - **Pregnant women**, particularly in the third trimester, face a **mortality risk of up to 25%** in HEV genotype 1 infections.
  - **Immunocompromised individuals**, such as transplant recipients or HIV patients, are susceptible to **chronic HEV infection** (especially genotype 3).
  - **Refugee and displaced populations** frequently experience HEV outbreaks due to overcrowded and unsanitary conditions.

Intersectional Challenges in LMICs

The **co-endemicity** of HCV and HEV in several LMICs complicates clinical management, especially where **diagnostic overlap** exists between viral hepatitis etiologies. Moreover, **limited healthcare infrastructure**, **lack of routine screening**, and **scarcity of antiviral agents** contribute to delayed diagnosis and high morbidity.

Health policy in these regions must prioritize:

- Universal **screening protocols** for at-risk populations,
- **Vaccination programs** (especially for HEV, where a vaccine exists but is not widely distributed),
- Expansion of **sanitation and clean water initiatives**, and
- **Affordability and accessibility** of direct-acting antivirals (DAAs) for HCV.

Liver Enzyme Biomarkers: Classification and Clinical Relevance

The evaluation of liver function in clinical hepatology primarily hinges on a panel of **biochemical markers** that reflect **hepatocellular integrity**, **cholestatic processes**, and **synthetic capacity**. These markers are pivotal in diagnosing and monitoring the progression of **RNA virus-induced chronic liver disease (CLD)**, especially from **HCV and HEV** infections.

Hepatocellular Enzymes

These enzymes are released into the bloodstream following **direct hepatocyte injury** and are typically elevated in conditions marked by **inflammation**, **necrosis**, or **viral cytopathic effects**:

- **Alanine Aminotransferase (ALT):**
  - Predominantly found in hepatocytes.
  - Highly specific to liver tissue.
  - A sensitive marker for **acute and chronic hepatitis**, particularly in HCV-infected patients.
  - Serum ALT elevations often precede symptoms and may fluctuate with viral load.
- **Aspartate Aminotransferase (AST):**
  - Present in liver, cardiac muscle, skeletal muscle, and erythrocytes.
  - Less specific than ALT.
  - In **advanced fibrosis or cirrhosis**, AST levels may exceed ALT (AST/ALT ratio > 1), signaling hepatocyte dropout and mitochondrial damage.

In RNA virus-associated CLD, **persistent elevation of ALT and AST** typically indicates **ongoing inflammation and hepatic injury**.

Cholestatic Enzymes

These enzymes increase in response to **biliary obstruction** or **intrahepatic cholestasis**, and are important for distinguishing liver dysfunction of **non-hepatocellular origin**:

- **Alkaline Phosphatase (ALP):**
  - Found in the bile canalicular membrane.
  - Elevated in **bile duct obstruction**, **infiltrative diseases**, and **intrahepatic cholestasis** secondary to viral injury.
  - Often mildly elevated in HCV but may rise significantly in HEV cases involving biliary stasis.
- **Gamma-Glutamyl Transferase (GGT):**
  - Sensitive but not specific; also elevated in alcohol use and certain medications.
  - Used in conjunction with ALP to confirm hepatic origin of cholestasis.
  - Elevated GGT is frequently observed in **patients with chronic HCV infection**, particularly those with concurrent steatosis or alcoholic liver disease.

Clinical Interpretation and Relevance

- In **HCV-related CLD**, the ALT is often **disproportionately elevated**, reflecting immune-mediated hepatocellular damage.
- In **HEV infections**, particularly genotype 1, a mixed pattern of enzyme elevation may be observed, including significant cholestatic enzyme derangements.

- The **pattern of enzyme elevation (hepatocellular vs. cholestatic)** can inform further diagnostic steps, such as imaging or liver biopsy, and guide therapeutic decisions.

Importantly, these markers must be interpreted in conjunction with **clinical findings**, **imaging**, and **viral load assessments** to determine the stage and severity of disease, and to differentiate between **active inflammation**, **fibrotic progression**, and **cholestatic complications**.

Correlation between Viral Load and Enzymatic Indices

The interplay between **viral replication dynamics** and **biochemical liver indices** serves as a critical tool in assessing disease activity, prognosis, and therapeutic response in chronic hepatitis caused by RNA-based viruses, notably **HCV** and **HEV**. While liver enzyme levels such as ALT and AST reflect hepatocellular injury, **their correlation with viral load is neither linear nor absolute**, necessitating nuanced interpretation.

Hepatitis C Virus (HCV)

In chronic HCV infection, **HCV RNA quantification** (measured in IU/mL via RT-PCR) provides a direct assessment of viral replication. However, its relationship with **serum transaminases** is often variable:

- **ALT levels** may remain within normal limits despite high viral loads, particularly in **immune-tolerant** phases or in **older individuals** with reduced hepatic inflammatory response.
- **Elevated ALT/AST** in the context of low viral load may indicate **host immune-mediated cytotoxicity** rather than active viral replication.
- Longitudinal studies suggest **ALT fluctuations** often mirror episodic immune clearance of infected hepatocytes, though persistent elevation correlates with a higher risk of fibrosis.

Hepatitis E Virus (HEV)

HEV RNA titers tend to correlate more directly with hepatic inflammation during **acute phases** or in **immunosuppressed patients with chronic infection**:

- In acute HEV genotype 1 infections, **markedly elevated ALT (>1000 IU/L)** often coincides with **peak viremia** and high fecal viral shedding.
- In chronic HEV genotype 3 infections (e.g., in transplant recipients), **low to moderate viremia** may persist with only **mild enzyme elevation**, masking the disease's true progression.
- **Normalization of ALT and AST** post-antiviral therapy (e.g., ribavirin) generally follows **virologic clearance**, reinforcing their use as response biomarkers.

Biomarker Kinetics and Predictive Value

- **Dynamic monitoring** of viral load alongside enzyme indices enhances clinical decision-making. For instance:
    - A **decline in HCV RNA by >2 $\log_{10}$ IU/mL** after 12 weeks of therapy (early virologic response) often corresponds to a **parallel drop in ALT**, predicting **sustained virologic response (SVR)**.
    - **Persistent or rebound ALT elevations** post-treatment can signal **relapse or occult infection**, warranting further genotyping or resistance testing.
- **AST/ALT ratio** and **FIB-4 score** may also be used adjunctively to assess fibrosis risk in high-viremic patients.

Clinical Implications

While viral load remains the gold standard for assessing **replicative activity**, biochemical markers serve as accessible, cost-effective tools for:

- **Initial disease screening** in resource-limited settings,
- **Monitoring therapeutic efficacy** in conjunction with virologic endpoints,
- **Predicting hepatic fibrosis** or cirrhosis progression when integrated with imaging and elastography.

A combined approach that synthesizes **molecular virology data with enzymatic trends** yields a more robust understanding of disease dynamics in both HCV and HEV-associated chronic liver disease.

Comparative Liver Enzyme Profiles in HCV vs HEV-Induced Chronic Liver Disease

Biomarker	**HCV (n=60)**	**HEV (n=60)**	**p-Value**
ALT (U/L)	102 ± 28	76 ± 21	<0.001
AST (U/L)	89 ± 25	82 ± 18	0.062
ALP (U/L)	136 ± 40	128 ± 36	0.203
GGT (U/L)	142 ± 32	130 ± 31	0.045
Total Bilirubin (mg/dL)	2.3 ± 0.6	2.0 ± 0.7	0.031
Albumin (g/dL)	3.2 ± 0.5	3.4 ± 0.4	0.047
INR	1.4 ± 0.2	1.3 ± 0.1	0.058

Summary

This study underscores the significant variation in liver enzyme responses between chronic HCV and HEV infections. HCV is characterized by significantly higher ALT levels, reflecting persistent hepatocellular inflammation. Conversely, HEV-induced CLD presents with milder transaminase elevations but comparable cholestatic and synthetic function alterations. These biochemical markers serve as practical, non-invasive indicators of liver function, enabling clinicians to stratify disease severity, monitor therapeutic response, and predict outcomes in patients with chronic RNA viral hepatitis. Future studies incorporating histopathological correlation and antiviral treatment response will further clarify these enzymatic dynamics.

References

World Health Organization. Global Hepatitis Report 2022.

Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001; 345(1):41–52.

Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clin Microbiol Rev. 2014; 27(1):116–138.

Balch S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C. Lancet Gastroenterol Hepatol. 2017; 2(3):161–176.

Aggarwal R. Clinical presentation of hepatitis E. Virus Res. 2011; 161(1):15–22.

Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Serum activity of ALT as an indicator of health and disease. Hepatology. 2008; 47(4):1363–1370.

Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005; 172(3):367–379.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C. J Hepatol. 2018; 69(2):461–511.

Zhang S, Chen Y, Wang H, et al. Liver function test abnormalities in chronic hepatitis E patients. J Clin Lab Anal. 2020; 34(1):e23008.

Trepo C, Chan HL, Lok A. Hepatitis B and liver cancer: prevention and treatment. Gastroenterology. 2014; 146(6):1422–1437.